MYGN Myriad Genetics, Inc.

$MYGN That’s it—no more buying stocks that announce positive news; it’s all just a scam to defraud traders.

All WINNERS 🏆 last 4 weeks. Become a men and get up to 3 picks daily except Friday. Trending: $MYGN $RAPP $COMP $TGTX

$MYGN This company was hovering around 3 for a long time. There was a reason for that , with Declining business , growth installed and decreasing revenue. With DEBTs and high interest looming, sold one business. Another 2 left but Revenue will get a big hit with close to 100 million stocks. Back to 3 , soon.

🌅 Watchlist part 1 ✅ $MYGN low 5.2 support, above 5.5, potential to 6/6.5 ✅ $WORX low 3.8 support, above 4.25, potential to 4.3/5 ✅ $FRTT .6 support, above .85, potential to 1/1.4 ✅ $SAIQ 4.4 support, above 5, potential to 5.5/5.8 ✅ $AIXI 2.5 support, above 3, potential to 3.5/4.5 🎯 Ideal stop loss below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D

if u were running $MYGN, what would u do with 210M in cash from Labcorp for the prenatal testing business? thats about half the company's market value on monday. management says the money backs the cancer testing side. reinvest, shrink the share count, or a deal?

$MYGN Looks like the strength is fading today. The big question is, what happens tomorrow?

$MYGN While November 4 will give management an opportunity to explain the future, many issues: - Limited competitive moat: Multiple established competitors offer similar diagnostic services. - Poor pricing power: Increasing test volumes haven't reliably translated into increasing revenue. - Questionable execution: Management's substantial guidance reduction undermines confidence. - Uncertain turnaround: Selling the prenatal business may improve the balance sheet, but it doesn't automatically make the remaining operations attractive.

$MYGN DECLINING BUSINESS. Recent performance is under pressure from lower reimbursement per test and declining prenatal testing volume Also, declining cancer and mental health revenue. This stock will go back to 3, eventually.

$MYGN Selling the prenatal business to $LH for 210 million dollars in cash, plus inventory at closing. The stock closed up 31.6% Tuesday, and the math kinda explains it, that cash is roughly 52% of what the whole company was worth at Monday's close. Prenatal was the shrinking piece anyway. Q2 revenue fell 16% to 39.8 million dollars on 9% lower volume, and Labcorp expects about 160 million dollars of revenue from the business in its first year, so Myriad is getting roughly 1.3x sales for a segment that was shrinking.

$MYGN $SPCX study, adapt, evolve. What goes into a real trade plan? ✍️ Our rule for premium alerts is six things, written down before anything is published: entry, stop, target, catalyst, time horizon and the chart. Which of the six do you skip most often in your own planning? Be honest. Time horizon is the one most people admit to.

$MYGN MYGN is on fire, near 5.73, up about 36.10 percent, after Piper Sandler upgraded it to Neutral from Underweight. Piper also raised its price target to 5 from 2. Here's the part I find interesting: the stock is now trading above the new target, so the move is bigger than what the call alone would justify. A jump this size on an upgrade from a bearish stance often means a crowd of bears had to cover, but that's my guess, not something I can confirm. For context, the stock was around 4.28 earlier this month and was down roughly a third for the year, trading at about 0.4 times forward sales. Its 52 week range runs from 2.74 to 8.59. I'd watch whether it holds these gains. Follow me for more on the diagnostics names.

$MYGN We did a deep dive on Myriad Genetics. • Gene-test maker sells prenatal unit to Labcorp for $210M, ~55% of pre-news market value • Without it, trailing revenue was ~$635.5M vs a $615.0M loan floor that steps up • Next: Nov 4 results Full report linked in the replies.

$MYGN Watching a movie is better than following a "dead" stock that fails to react to positive news.

$MYGN +37% to 5.79 on about 10x normal volume. Gapped from 4.21 to 5.34 and pressing the 5.95 high. Hold the 5.25 gap low and 6+ is in play, lose it and the gap starts filling 🔥

$MYGN hmm, I wonder when will this clown start spamming bearish posts. Let's give him few mins

$MYGN Done. BIG DEBT. Double trouble with Double top at 5.95. BIG DEBT. Profit business sold. Declining business will have a lot less revenue next quarter. Take your profits and run folks.

$MYGN anyone know what the highest price was for this stock. If all goes according to plan this stock price should quadruple in a month and then who knows what will happen. I only wish I had the capital to buy a thousand shares. Thus could make a lot of people millionaires in a year

Myriad Genetics agreed to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value at closing. The deal includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which generated approximately $160 million in revenue over the past 12 months and served more than 600,000 patients, implying a purchase price of roughly 1.3x trailing revenue, excluding inventory. Myriad CEO Sam Raha said the divestiture should support revenue growth and profitability while strengthening the balance sheet to fund strategic investments in oncology care. Labcorp expects the acquisition to add approximately $160 million in first-year revenue and modestly increase adjusted earnings. It aims to reach its Diagnostics segment’s average margins by the end of the second year, following integration. The transaction remains subject to regulatory approval and customary closing conditions, with completion expected in early 2027. $MYGN $LH

$MYGN This sick market—whether green or red—puts pressure on the stock.she will runs soon has great news deserves at least 12+ or more

$MYGN it's going to sell a big part of it's $ making business so now even worse debt & losses